ZEALAND PHARMA AS

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1998-01-01

Employees: 150

Market Cap: $9.1B

Website: https://www.zealandpharma.com/

Clinical Trials

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Dasiglucagon

First Posted Date: 2018-09-28

Last Posted Date: 2021-05-19

Lead Sponsor: Zealand Pharma

Target Recruit Count: 45

Registration Number: NCT03688711

Locations: 🇺🇸
Rainier Clinical Research, Inc., Renton, Washington, United States
🇺🇸
AMCR Institute, Escondido, California, United States
🇺🇸
ProSciento, Inc., Chula Vista, California, United States

Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

Phase 3

Completed

Conditions: Hypoglycemia

Interventions: Drug: GlucaGen HypoKit
Drug: placebo
Drug: dasiglucagon

First Posted Date: 2018-09-12

Last Posted Date: 2021-06-30

Lead Sponsor: Zealand Pharma

Target Recruit Count: 42

Registration Number: NCT03667053

Locations: 🇺🇸
AMCR Institute, Inc, Escondido, California, United States
🇺🇸
Indiana University, Department of Pediatrics, Indianapolis, Indiana, United States
🇩🇪
Auf der Bult - Diabetes Center for Children, Hannover, Germany

and more 2 locations

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Placebo
Drug: Dasiglucagon
Drug: GlucaGen

First Posted Date: 2017-12-20

Last Posted Date: 2021-06-10

Lead Sponsor: Zealand Pharma

Target Recruit Count: 170

Registration Number: NCT03378635

Locations: 🇦🇹
Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪
Profil, Neuss, Germany
🇺🇸
ProSciento, Chula Vista, California, United States

and more 1 locations

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Glepaglutide

First Posted Date: 2017-09-12

Last Posted Date: 2017-12-22

Lead Sponsor: Zealand Pharma

Target Recruit Count: 75

Registration Number: NCT03279302

Locations: 🇺🇸
Covance CRU, Dallas, Texas, United States

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: GlucaGen
Drug: dasiglucagon

First Posted Date: 2017-07-13

Last Posted Date: 2021-05-04

Lead Sponsor: Zealand Pharma

Target Recruit Count: 112

Registration Number: NCT03216226

Locations: 🇨🇦
LMC Calgary, Calgary, Canada
🇦🇹
CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪
Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg, Germany

and more 4 locations

Feasibility Trial Testing the Bionic Pancreas With ZP4207

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin Lispro
Drug: ZP4207 (dasiglucagon)
Drug: Glucagon
Device: iPhone-based bionic pancreas
Device: iLet-based bionic pancreas

First Posted Date: 2016-11-22

Last Posted Date: 2021-03-23

Lead Sponsor: Zealand Pharma

Target Recruit Count: 13

Registration Number: NCT02971228

Locations: 🇺🇸
MGH Diabetes Center, Boston, Massachusetts, United States

ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

Phase 2

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Drug: ZP4207(dasiglucagon) glucagon analogue
Drug: Glucagon (Native glucagon)

First Posted Date: 2016-09-27

Last Posted Date: 2017-04-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 38

Registration Number: NCT02916251

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Phase 2

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: ZP1848

First Posted Date: 2016-02-24

Last Posted Date: 2017-06-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 18

Registration Number: NCT02690025

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Phase 2

Completed

Conditions: Hypoglycemia

Interventions: Drug: ZP4207
Drug: GlucaGen

First Posted Date: 2016-01-21

Last Posted Date: 2016-06-15

Lead Sponsor: Zealand Pharma

Target Recruit Count: 81

Registration Number: NCT02660008

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

Phase 1

Completed

Conditions: Hypoglycemia

Interventions: Drug: ZP4207
Drug: Placebo

First Posted Date: 2015-03-17

Last Posted Date: 2015-11-11

Lead Sponsor: Zealand Pharma

Target Recruit Count: 24

Registration Number: NCT02390141

Locations: 🇩🇪
Profil GmbH, Neuss, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy